Uma Borate

11PUBLICATIONS
93CO-AUTHORS
Haematological tumoursGene and molecular therapyRehabilitationMolecular medicineCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 25, 2025
A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.

Eric D Eisenmann, Ronan Swords, Ying Huang

|Jun 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.

Joshua F Zeidner, Tara L Lin, Rina Li Welkie

|May 07, 2025
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.

Amy E DeZern, Sylvain Thepot, Stephane de Botton

|Dec 09, 2024
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes.

Jacqueline S Garcia, Uwe Platzbecker, Olatoyosi Odenike

|Sep 06, 2024
Healthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database Study.

Uma Borate, Karen Seiter, Ravi Potluri

|Oct 12, 2022
Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance.

Junhua Lyu, Yuxuan Liu, Lihu Gong

Pageof 2

Frequent Collaborators

3 joint publications

Alice S Mims

2 joint publications

David A Sallman

2 joint publications

Brian J Druker

2 joint publications

Mona Stefanos